News

2025/07/25: A joint press conference was held at Ube City Hall in Yamaguchi Prefecture on July 23, 2025 regarding the collaborative support for the Noile-Immune’s project by Yamaguchi Prefecture and Ube City. (2025/7/30 update); Noile-Immune's project, “Social implementation of world's first treatment for solid tumors by CAR-T cell therapy with next-generation immune-enhancing technology and formation of a wide-area collaboration base for research and development” was adopted for subsidies by Yamaguchi Prefecture and Ube City. On Wednesday, July 23, 2025, a joint press conference was held at the Ube City Hall in Yamaguchi Prefecture.
Details of the press conference are being reported by various media coverages.
(The articles are written in Japanese only, so sorry for your inconvenience)
（NHK 2025/7/24）
Article in Japanese
（KRY山口放送: KRY News 2025/7/24）
Article in Japanese
（山口新聞（電子版）:Yamaguchi shimbun 2025/7/24）
Article in Japanese
（宇部日報: Ube Nippo 2025/7/24）
Article in Japanese
（毎日新聞: THE MAINICHI NEWSPAPERS 2025/7/25）
Article in Japanese

2025/07/16: Notice of Project Adoption for Ube City Subsidy for Promoting Practical Application of Cutting-Edge Research and Development in Regenerative Medicine, etc.

2025/07/15: Notice of Ending Collaboration with Daiichi Sankyo on Technology Assessment

2025/07/01: Notice of Subsidy Project Adoption for FY2025 Yamaguchi Advancements in Practical Application and Industrialization of Regenerative Medicine

2025/06/09: Notice of Completion of Clinical Trial Notification Submission of NIB103 Phase I Clinical Trial

2025/06/03: Poster Presentation at the American Society of Clinical Oncology (ASCO) for Phase I Study on Safety and Efficacy of Switchable CAR-T Cell Therapy with FY001 and CART001 in Patients with Relapsed/Refractory CD20-positive B-cell Non-Hodgkin Lymphoma (EPOC1803)

2025/02/19: Publishment of a dialogue article about Koji Tamada, President and CEO of Noile-Immune Inc., in Nikkei Biotechnology and Business; A dialogue article between Keiichi Fukuda, CEO, Representative Director of the Board of Heartseed Inc. and Koji Tamada, Representative Director, President & CEO of Noile-Immune Biotech Inc., which took place at the Summit of Startups from Keio University School of Medicine, was published in Nikkei Biotechnology and Business (February 19, 2025).
Topic : https://bio.nikkeibp.co.jp/atcl/news/p1/25/02/13/12960/(This article is only written by Japanese, so sorry for your inconvenience)

2025/02/04: Notice of Option Agreement with the University of Tokyo for Polymer Compound for Nucleic Acid Delivery

2025/01/31: An interview article about Koji Tamada, Professor at Yamaguchi University and President and CEO of Noile-Immune, entitled "Cutting-Edge Medicine: Featured Keywords", was published in the March issue of "KATEIGAHO" (on sale January 31, 2025).(This article is only written by Japanese, so sorry for your inconvenience)

2025/01/17: Publishment of a newspaper article about the "<Osaka> Bio IR Day" hosted by the Nihon Securities Journal Inc. covered Noile-Immune (This article was written by only Japanese, Sorry for your inconvenience); A newspaper article about the "<Osaka> Bio IR Day", company briefing sessions for individual investors, hosted by the Nihon Securities Journal Inc. held on Tuesday, December 10, covered Noile-Immune was published.

2024/12/16: (Correction) Partial Correction to “Notice of Re-prioritization of In-house Drug Discovery Pipelines and Change in Use of Funds Raised at the Time of Listing” (Japanese version already released on October 11)

2024/11/19: Noile-Immune's Director, Tsutom Tokashiki, will participate in a "Company Presentation (Part 3 :14:10-14:45)" and a "Panel Discussion (Part 4 :15:00-16:00)" at the "<Osaka> Bio IR Day" (at Asahi Seimei Hall (Osaka Asahi Seimei Kan 8F)) hosted by the Nihon Securities Journal Inc. on Tuesday, December 10. Reference Link is Japanese only, we're sorry for your inconvenience.; Reference Link is Japanese only, we're sorry for your inconvenience.

2024/11/11: Poster Presentation at SITC Quantitative Clinical Pharmacology and Mechanistic Modeling in a Phase I Clinical Trial of CAR-T Cell Therapy (NIB102) with Noile-Immune’s PRIME Technology

2024/10/28: Presentation at the Annual Meeting of Japan Society of Clinical Oncology (JSCO) Updated Results from First-in-Human Phase I Dose-Escalation Trial of CAR-T Cell Therapy (NIB102) with Noile-Immune’s PRIME Technology

2024/10/04: Exhibition by Noile-Immune at Japan Healthcare Venture Summit 2024 co-held with BioJapan 2024; Noile-Immune will exhibit at the Japan Healthcare Venture Summit (JHVS), which will be co-held with BioJapan 2024 at Pacifico Yokohama from Wednesday, October 9 to Friday, October 11, 2024. At the exhibition booth (Booth No.: V-62), Noile-Immune will introduce its proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy, and will make a presentation at the "JHVS SHOWCASE" held on the stage at the JHVS venue (Wednesday, October 9, 11:00-12:00 part). In addition, Noile-Immune will participate in the 1 on 1 meetings using the partnering system.